In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on ...

Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has suffered a setback as the therapy ...

including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 ...

It launched in October 2019 in the US with sales predictions of $2.5 billion or more at peak, but sales slumped 43% in the first quarter of 2021 to $39 million. Wet AMD is a leading cause of ...

(RTTNews) - Shares of Outlook Therapeutics Inc. (OTLK), a biopharmaceutical company specializing in ophthalmic treatments, are down over 70% in premarket trading, following mixed results from its ...

Don't Miss our Black Friday Offers: Opthea Limited is set to showcase its promising treatment for wet age-related macular degeneration, sozinibercept, at the upcoming FLORetina Congress in Italy.

In August, the FDA declined to approve ONS-5010 for wet AMD, citing specific manufacturing issues and the need for additional clinical evidence. However, the company plans to launch the drug next ...